(Q44571765)

4 December 2017

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias (English)

1 reference

4 December 2017

1 reference

Burke JM

1

1 reference

4 December 2017

Caron PC

2

1 reference

4 December 2017

Papadopoulos EB

3

1 reference

4 December 2017

Divgi CR

4

1 reference

4 December 2017

Sgouros G

5

1 reference

4 December 2017

Panageas KS

6

1 reference

4 December 2017

Finn RD

7

1 reference

4 December 2017

Larson SM

8

1 reference

4 December 2017

O'Reilly RJ

9

1 reference

4 December 2017

Scheinberg DA

10

1 reference

4 December 2017

Jurcic JG

11

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Bone Marrow Transplantation

4 December 2017

1 reference

4 December 2017

32

1 reference

4 December 2017

6

1 reference

4 December 2017

549-556

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704201

4 December 2017

0 references

cites work

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Total body irradiation before allogeneic bone marrow transplantation: is more dose better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first compl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

7 January 2021

Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

7 January 2021

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

7 January 2021

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704201

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704201

1 reference

4 December 2017

1 reference